CBS 2019
CBSMD教育中心
中 文

Congestive Heart Failure

Abstract

Recommended Article

Atrial Fibrillation and the Prognostic Performance of Biomarkers in Heart Failure Risk of Mortality Following Catheter Ablation of Atrial Fibrillation Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rate sST2 Predicts Outcome in Chronic Heart Failure Beyond NT−proBNP and High-Sensitivity Troponin T 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines Frequency, predictors, and prognosis of ejection fraction improvement in heart failure: an echocardiogram-based registry study Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction Novel percutaneous interventional therapies in heart failure with preserved ejection fraction: an integrative review

Clinical TrialVolume 71, Issue 11 Supplement, March 2018

JOURNAL:J Am Coll Cardiol. Article Link

Comparison Of High Shear Stress-Induced Thrombotic And Thrombolytic Effect Between Aspirin, Clopidogrel And Very Low Dose Rivaroxaban And Aspirin, Ticagrelor Treatments In Patients With Acute Coronary Syndrome

M Kim, KS Hyuk, JJ Park et al. Keywords: high shear stress; global thrombosis test;

ABSTRACT


BACKGROUND - Global thrombosis test (GTT) is a simple but useful method to measure high shear stress-induced whole blood thrombotic and endogenous thrombolytic activity and it may mimic platelet aggregation in acute coronary syndrome (ACS) condition more accurately compared to conventional platelet function tests. We compared GTT and conventional platelet function test (VerifyNow® test) in patients with ACS who were treated aspirin/ticagrelor (TICA) or aspirin/clopidogrel/very low dose rivaroxaban (RIVA).


METHODS - A total of 41 patients (TICA (n=24), RIVA (n=17)) who underwent percutaneous coronary intervention were consecutively enrolled. GTT and VerifyNow®test were performed at day 2 (D2) and day 30 (D30) after successful PCI. We compared occlusion time (OT), lysis time (LT), aspirin reaction unit (ARU) and P2Y12 reaction unit (PRU) between the two groups at D2 and D30.


RESULTS - There were no significant statistical differences in baseline clinical, angiographic and laboratory characteristics between the two groups. At D2, there were no significant differences in OT (483.5±94.4 sec vs. 540.1±146.2 sec, p=0.239), LT (1,952.2±1,420.9 sec vs. 1,919.2±1,125.4 sec, p=0.253) or ARU (490.0±79.3 vs. 455.9±73.3, p=0.102), but PRU was significantly lower in the TICA group (34.8±60.1 vs. 130.9±70.6, p<0.001). At D30, there were no significant differences in OT (553.5±111.1 sec vs. 634.2±152.0 sec, p=0.121), LT (1540.7±704.1 sec vs. 1679.2±529.4 sec, p=0.261) or ARU (441.4±83.9 vs. 468.8±69.7, p=0.144) between two groups, and PRU was consistently lower in the TICA group (34.6±36.1 vs. 164.8±70.6, p<0.001).


CONCLUSION - High shear stress-induced global thrombotic and lytic activity did not differ between the two antithrombotic regimens although TICA showed more potent inhibition of ADP-induced platelet aggregation.